JP3026435B1 - Leukemia cell growth inhibitor and method for producing the same - Google Patents

Leukemia cell growth inhibitor and method for producing the same

Info

Publication number
JP3026435B1
JP3026435B1 JP11148440A JP14844099A JP3026435B1 JP 3026435 B1 JP3026435 B1 JP 3026435B1 JP 11148440 A JP11148440 A JP 11148440A JP 14844099 A JP14844099 A JP 14844099A JP 3026435 B1 JP3026435 B1 JP 3026435B1
Authority
JP
Japan
Prior art keywords
cell growth
leukemia
leukemia cell
growth inhibitor
dietary fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP11148440A
Other languages
Japanese (ja)
Other versions
JP2000336036A (en
Inventor
英樹 大庭
剛 坂木
浩毅 安藤
郁子 古川
徹郎 國生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagoshima-Ken Kagoshima-Shi Kagoshima-Ken
Original Assignee
Kagoshima-Ken Kagoshima-Shi Kagoshima-Ken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagoshima-Ken Kagoshima-Shi Kagoshima-Ken filed Critical Kagoshima-Ken Kagoshima-Shi Kagoshima-Ken
Priority to JP11148440A priority Critical patent/JP3026435B1/en
Application granted granted Critical
Publication of JP3026435B1 publication Critical patent/JP3026435B1/en
Publication of JP2000336036A publication Critical patent/JP2000336036A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

【要約】 【課題】 入手容易な原料から、白血病細胞の増殖を効
果的に阻害し、白血病治療に有効な白血病細胞増殖阻害
剤を得ることを目的とする。 【解決手段】 植物木質組織由来の非セルロース性食物
繊維を主成分としてなる白血病細胞増殖阻害剤であり、
植物木質組織粉末に、100〜140℃の加圧熱水を接
触させて可溶成分を抽出除去したのち、その残留分に1
40〜220℃の加圧熱水を接触させて分解及び抽出を
行わせ、非セルロース性食物繊維を分離して製造する。
An object of the present invention is to obtain a leukemia cell proliferation inhibitor that is effective in treating leukemia by effectively inhibiting the proliferation of leukemia cells from easily available raw materials. A leukemia cell growth inhibitor comprising non-cellulosic dietary fiber derived from woody tissue of a plant as a main component,
The plant woody tissue powder is brought into contact with pressurized hot water at 100 to 140 ° C. to extract and remove soluble components.
Decomposition and extraction are performed by contacting hot pressurized water at 40 to 220 ° C. to separate and produce non-cellulosic dietary fiber.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、新規な白血病細胞
の増殖阻害剤、さらに詳しくいえば、植物組織から特定
な条件下で抽出された食物繊維を主成分とする白血病細
胞増殖阻害剤及びその製造方法に関するものである。
TECHNICAL FIELD The present invention relates to a novel leukemia cell growth inhibitor, and more particularly, to a leukemia cell growth inhibitor containing dietary fiber as a main component extracted from plant tissue under specific conditions, and to its use. It relates to a manufacturing method.

【0002】[0002]

【従来の技術】白血病は、骨髄の白血球細胞が自律増殖
する疾患、いわゆる血液のがんであって、貧血、白血球
増多症、血小板減少症などを起こし、しばしば肝、脾、
リンパ節などの他の臓器に二次的浸潤病巣(転移)又は
二次的造血病巣をつくることが知られている。
2. Description of the Related Art Leukemia is a disease in which white blood cells in the bone marrow autonomously proliferate, so-called cancers of the blood, which cause anemia, leukocytosis, thrombocytopenia, etc.
It is known to create secondary invasive foci (metastasis) or secondary hematopoietic foci in other organs such as lymph nodes.

【0003】このような白血病の治療薬としては、これ
まで種々の合成物質、抗生物質、天然由来物質、あるい
はインターフェロン、インターロイキン、TNF(腫瘍
壊死因子)、CSF(コロニー形成刺激因子)抑制物質
などのバイオテクノロジー製品が開発されている。これ
らは、白血病細胞に作用して、その増殖を阻害したり、
壊死すなわちネクローシスを起こさせて、疾病を治療す
るものである。
[0003] As such a therapeutic agent for leukemia, various synthetic substances, antibiotics, naturally occurring substances, interferon, interleukin, TNF (tumor necrosis factor), CSF (colony formation stimulating factor) inhibitor and the like have hitherto been used. Biotechnology products are being developed. These act on leukemia cells to inhibit their growth,
It causes necrosis or necrosis to treat the disease.

【0004】しかしながら、これらの白血病治療薬は、
原料が入手しにくい上に、製造方法が煩雑でコスト高に
なるのを免れない。他方、細胞毒性を誘導することによ
り特定の細胞に対して細胞増殖阻害を惹起させるものと
して、細胞増殖阻害剤が知られているが、この細胞毒性
発現機構は非常に複雑であり、どのような物質がどのよ
うな細胞に対して細胞毒性を生じさせるかは、全く予測
不可能であり、白血病細胞に対して有効な細胞増殖阻害
剤を得ることは非常に困難であった。
[0004] However, these drugs for treating leukemia are:
In addition to difficulties in obtaining raw materials, it is unavoidable that the production method is complicated and costly. On the other hand, a cell growth inhibitor is known to induce cell growth inhibition in specific cells by inducing cytotoxicity. However, the mechanism of this cytotoxicity expression is very complicated. It is completely unpredictable to what cell the substance causes cytotoxicity, and it has been very difficult to obtain an effective cell growth inhibitor for leukemia cells.

【0005】[0005]

【発明が解決しようとする課題】本発明は、入手容易な
原料から、白血病細胞の増殖を効果的に阻害し、白血病
治療に有効な白血病細胞増殖阻害剤を得ることを目的と
してなされたものである。
SUMMARY OF THE INVENTION The object of the present invention is to provide a leukemia cell growth inhibitor which effectively inhibits the growth of leukemia cells and is effective for the treatment of leukemia from readily available raw materials. is there.

【0006】[0006]

【課題を解決するための手段】本発明者らは、白血病細
胞の増殖を阻害する物質を開発するために種々研究を重
ねた結果、植物木質組織を特定の条件で処理し、抽出し
た非セルロース性食物繊維がT細胞性白血病細胞に対し
て良好な増殖阻害効果を示すことを見出し、この知見に
基づいて本発明をなすに至った。
Means for Solving the Problems The present inventors have conducted various studies to develop a substance that inhibits the growth of leukemia cells. The present inventors have found that dietary fiber has a good growth inhibitory effect on T-cell leukemia cells, and have accomplished the present invention based on this finding.

【0007】すなわち、本発明は、植物木質組織由来の
非セルロース性食物繊維を主成分としてなる白血病細胞
増殖阻害剤、及び植物木質組織粉末に、100〜140
℃の加圧熱水を接触させて可溶成分を抽出除去したの
ち、その残留分に140〜220℃の加圧熱水を接触さ
せて分解及び抽出を行わせ、非セルロース性食物繊維を
分離することを特徴とする白血病細胞増殖阻害剤の製造
方法を提供するものである。
That is, the present invention relates to a leukemia cell growth inhibitor comprising a non-cellulosic dietary fiber derived from plant wood tissue as a main component and a plant wood tissue powder,
After extracting soluble components by contacting with hot pressurized water at a temperature of 140 ° C., 140 ° C. to 220 ° C. is contacted with hot water at a temperature of 140 to 220 ° C. to cause decomposition and extraction to separate non-cellulosic dietary fiber. And a method for producing a leukemia cell growth inhibitor.

【0008】[0008]

【発明の実施の形態】本発明の白血病細胞増殖阻害剤
は、植物木質組織を原料として用い、これを特定の条件
で処理し、抽出されるものであるが、この植物木質組織
としては、特に制限はなく、例えば竹類、広葉樹、針葉
樹などのいずれに属するものでもよい。このような木質
の例としては、ソテツ、イチョウ、マツ、イチイ、モク
レン、クルミ、ヤマモモ、ブナ、ツバキ、アオイ、ヤナ
ギ、ツツジ、ウメ、カキ、バラ、ヒノキ、スギ、ヤシ、
ニレなどの木質部分を挙げることができる。本発明の白
血病細胞増殖阻害剤として用いるには、リグニンやヘミ
セルロースを比較的多量に含有するものが好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION The leukemia cell growth inhibitor of the present invention is obtained by using plant wood tissue as a raw material, treating it under specific conditions, and extracting the wood tissue. There is no limitation, and for example, those belonging to any of bamboos, hardwoods, conifers and the like may be used. Examples of such woody materials include cycads, ginkgo, pine, yew, magnolia, walnut, bayberry, beech, camellia, mallow, willow, azalea, plum, oyster, rose, cypress, cedar, palm,
Woody parts such as elm can be mentioned. For use as the leukemia cell growth inhibitor of the present invention, those containing a relatively large amount of lignin or hemicellulose are preferred.

【0009】本発明方法によれば、これらの植物木質組
織を粉末状としたものを原料とし、加圧熱水により2段
階で処理し、抽出する。すなわち、先ず、50〜500
μmの粒径の原料粉末を、例えば加圧熱水流通式反応装
置に装入し、100〜140℃の加圧熱水で処理する
と、色素やタンニンなどの細胞内含有成分が容易に抽出
される。この処理を約20〜60分間続けると、上記の
含有成分がほぼ完全に除去されるので、次いで140〜
220℃の加圧熱水と連続的に接触させると、木質部分
が加圧熱水によって加水分解され溶出してくる。この溶
出物を捕集し、凍結乾燥すると、淡かっ色の粉末とし
て、本発明の白血病細胞増殖阻害剤が得られる。このよ
うにして得られた白血病細胞増殖阻害剤は、糖分析及び
紫外吸収スペクトル分析の結果、ヘミセルロース由来の
単糖、水溶性オリゴ糖、水溶性リグニン及び糖−リグニ
ン結合体を主成分として含有することが分った。
According to the method of the present invention, the woody tissue of these plants is used as a raw material, and is treated and extracted with hot pressurized water in two stages. That is, first, 50 to 500
Raw material powder having a particle size of μm is charged into, for example, a pressurized hot water flow type reaction apparatus and treated with pressurized hot water at 100 to 140 ° C., whereby components contained in cells such as pigments and tannin are easily extracted. You. When this treatment is continued for about 20 to 60 minutes, the above-mentioned components are almost completely removed.
When the wood part is continuously contacted with pressurized hot water at 220 ° C., it is hydrolyzed by the pressurized hot water and eluted. The eluate is collected and freeze-dried to obtain the leukemia cell growth inhibitor of the present invention as a pale brown powder. The leukemia cell growth inhibitor thus obtained contains, as a main component, a hemicellulose-derived monosaccharide, a water-soluble oligosaccharide, a water-soluble lignin and a sugar-lignin conjugate as a result of sugar analysis and ultraviolet absorption spectrum analysis. I understood that.

【0010】本発明の細胞増殖阻害剤は、非経口的に投
与することができる。その投与量は、治療すべき疾患の
程度により増減されるが、通常1日当り0.01〜10
mg/kgの範囲内で選ばれる。このものは、細胞毒性
による細胞増殖阻害作用を示すため、他の細胞増殖阻害
剤よりも少ない量の投与で十分な効果が得られる。ま
た、このものは0.1〜10%濃度の水性溶液として製
剤化されるが、所望に応じ溶解補助剤、緩衝剤、等張化
剤、安定剤、保存剤、無痛化剤など注射液に慣用されて
いる添加剤を併用することもできる。
[0010] The cell growth inhibitor of the present invention can be administered parenterally. The dose varies depending on the degree of the disease to be treated, but is usually 0.01 to 10 per day.
It is selected within the range of mg / kg. Since this compound exhibits a cell growth inhibitory effect due to cytotoxicity, a sufficient effect can be obtained by administering a smaller amount than other cell growth inhibitors. It is formulated as an aqueous solution having a concentration of 0.1 to 10%, and may be used as an injection, such as a solubilizing agent, a buffer, an isotonic agent, a stabilizer, a preservative, or a soothing agent, if desired. Commonly used additives can be used in combination.

【0011】一方、この分解抽出物は、少量において白
血病細胞増殖阻害剤として用いられるが、食物繊維を多
く含有しているため、一般食品への添加により機能性食
品としての素材にもなりうる。
On the other hand, this decomposed extract is used as a leukemia cell growth inhibitor in a small amount, but contains a large amount of dietary fiber, so that it can be used as a functional food by adding it to general foods.

【0012】[0012]

【実施例】次に、本発明を実施例により詳細に説明する
が、本発明はそれらの例によってなんら限定されるもの
ではない。
Next, the present invention will be described in detail with reference to examples, but the present invention is not limited to these examples.

【0013】実施例1 177〜250μmの粒径に調整した竹粉末(組成、ア
ルコール−ベンゼン抽出物:7重量%、リグニン:21
重量%、ヘミセルロース:25重量%、セルロース:4
8重量%)1gを、両端が金属製焼結フィルター(孔径
5μm)でキャップされているステンレス鋼製固定床型
反応器(φ10.2mm、長さ46.7mm、3.6m
l容)に仕込み、蒸気化しないように100気圧に加圧
された135℃の加圧熱水を通水速度10ml/min
で約15分間流して可溶成分を除去した。続いて200
℃の熱水を15分間連続的に通水して、分解生成物を回
収した。このとき、反応器出口から分解され熱水に可溶
化して流出してきた成分の二次分解を抑制するため、直
ちに流速2.5ml/minの冷却水と接触させた。得
られた抽出液を凍結乾燥し、仕込量当りの回収率を求め
たところ、最初の可溶成分(グループI)の収率が12
重量%、分解生成物(グループII)の回収率が43重
量%であった。
Example 1 Bamboo powder adjusted to a particle size of 177 to 250 μm (composition, alcohol-benzene extract: 7% by weight, lignin: 21)
% By weight, hemicellulose: 25% by weight, cellulose: 4
1 g of a stainless steel fixed-bed reactor (φ10.2 mm, length 46.7 mm, 3.6 m) capped at both ends with a sintered metal filter (pore diameter 5 μm).
1 volume), and pressurized hot water of 135 ° C., which is pressurized to 100 atm so as not to evaporate, is passed at a flow rate of 10 ml / min.
For about 15 minutes to remove soluble components. Then 200
Decomposition products were collected by continuously passing hot water of 15 ° C. for 15 minutes. At this time, in order to suppress the secondary decomposition of the components decomposed from the reactor outlet and solubilized in hot water and flowed out, the components were immediately brought into contact with cooling water at a flow rate of 2.5 ml / min. The obtained extract was freeze-dried and the recovery rate per charged amount was determined. The yield of the first soluble component (group I) was 12%.
% By weight, and the recovery of the decomposition product (Group II) was 43% by weight.

【0014】このようにして加圧熱水の2段階昇温によ
って得られたグループI及びIIの糖分析及び紫外吸収
スペクトルを測定した結果、それぞれの糖組成を異にし
たものであり、グループIIには主としてヘミセルロー
ス由来のアラビノース、キシロース及びキシロオリゴ糖
が存在することが分った。このものは205nmと28
0nmの芳香族系吸収波長を持ち、かつその吸収が強い
ことから、水溶性リグニン及び糖−リグニン結合体が共
存しているものと考えられる。
As a result of the analysis of the sugars and the ultraviolet absorption spectrum of the groups I and II obtained by the two-step heating of the pressurized hot water as described above, the sugar compositions were different from each other. Was found to contain mainly arabinose, xylose and xylooligosaccharide derived from hemicellulose. This is 205 nm and 28
Since it has an aromatic absorption wavelength of 0 nm and its strong absorption, it is considered that water-soluble lignin and a sugar-lignin conjugate coexist.

【0015】以上のことから、加圧熱水の2段階昇温を
行うと、比較的低温の加圧熱水で抽出されやすい細胞内
含有成分(グループI)が135℃の加圧熱水で分離さ
れ、ヘミセルロース由来の単糖、オリゴ糖及び水溶性リ
グニン、糖−リグニン結合体を含む熱水分解物が200
℃の加圧熱水によって分離されることが分った。
From the above, when the temperature of the pressurized hot water is raised in two stages, the intracellular components (group I) which are easily extracted by the relatively low-temperature pressurized hot water can be extracted with the 135 ° C. pressurized hot water. The hydrothermal decomposition product containing the separated hemicellulose-derived monosaccharide, oligosaccharide, water-soluble lignin and sugar-lignin conjugate was 200
It was found to be separated by hot pressurized water at ℃.

【0016】実施例2 実施例1で得られたグループIIの凍結乾燥物を用い、
以下の手順で水溶性画分を分画した。200mgの凍結
乾燥物を、1.5mlの蒸留水に可溶化したのち、0.
2μmのフィルターで余剰固形分をろ過したろ液を水溶
性分解抽出物Aとした。同様に凍結乾燥物200mgを
用いて5mlのエタノールで脂溶性成分を除去し、さら
にエタノール抽出後の固形残渣を1.5mlの蒸留水に
可溶化し、0.2μmのフィルターでろ過したろ液を水
溶性分解抽出物Bとし、それぞれを白血病細胞増殖阻害
試験に供した。白血病細胞増殖阻害試験は、前述のA及
びBの分解抽出物を代表的な白血病細胞である3種類の
T細胞性白血病細胞(RPMI8402、MOLT4、
Jurkat)及びB細胞性白血病細胞(NALM6)
の全4種に対して行った。
Example 2 Using the freeze-dried product of Group II obtained in Example 1,
The water-soluble fraction was fractionated by the following procedure. After solubilizing 200 mg of the lyophilized product in 1.5 ml of distilled water, 0.1%
The filtrate obtained by filtering excess solid content with a 2 μm filter was used as a water-soluble decomposition extract A. Similarly, 200 mg of the lyophilized product was used to remove fat-soluble components with 5 ml of ethanol, and the solid residue after ethanol extraction was solubilized in 1.5 ml of distilled water, and the filtrate filtered with a 0.2 μm filter was used. Each extract was used as a water-soluble decomposition extract B and subjected to a leukemia cell growth inhibition test. In the leukemia cell proliferation inhibition test, the decomposed extracts of A and B described above were used as representative leukemia cells of three types of T-cell leukemia cells (RPMI8402, MOLT4,
Jurkat) and B-cell leukemia cells (NALM6)
For all four species.

【0017】白血病細胞阻害の測定法は、あらかじめ3
7℃、RPMI−1640培地で培養した白血病細胞
(90μl、2.22×105個/ml)を96枚のウ
ェルに分注し、さらに大気圧下、5%CO2湿潤空気中
で、37℃、24時間培養後、A及びBの分解抽出物を
100μg/ml、50μg/ml、25μg/ml、
12.5μg/ml、6.25μg/ml、3.125
μg/mlの濃度になるようにリン酸塩緩衝生理的食塩
水(pH7.4、Caイオン及びMgイオンは含まな
い)で調整したものを、それぞれ10μl添加後、大気
圧下、5%CO2湿潤空気中で、37℃、20時間培養
した。また、コントロールとして細胞懸濁液90μlに
リン酸塩緩衝生理的食塩水10μlを添加したものにつ
いても同様の処理を行った。24時間培養した培養液1
00μlについてセルティター(celltiter)
96(プロメガ社製)により分析し、分解抽出物の細胞
株に対する細胞増殖阻害活性を、ミトコンドリア脱水素
酵素の活性を指標として調べた。このとき、細胞増殖阻
害活性は細胞増殖阻害率(%)=100−(分解抽出物
を添加後24時間培養した培養液の590nmにおける
吸光度/コントロールの590nmにおける吸光度)×
100で表わした。その結果をグラフとして図1ないし
図4に示す。
The method of measuring leukemia cell inhibition is determined in advance by 3
Leukemia cells (90 μl, 2.22 × 10 5 cells / ml) cultured in RPMI-1640 medium at 7 ° C. were dispensed into 96 wells, and further incubated at 37 ° C. in 5% CO 2 humid air under atmospheric pressure. After culturing at 24 ° C. for 24 hours, 100 μg / ml, 50 μg / ml, 25 μg / ml,
12.5 μg / ml, 6.25 μg / ml, 3.125
[mu] g / ml phosphate buffered saline to a concentration of those prepared in (pH 7.4, Ca ions and Mg ions is not included), after each 10μl added, under atmospheric pressure, 5% CO 2 The cells were cultured in humid air at 37 ° C. for 20 hours. In addition, the same treatment was carried out for a control obtained by adding 10 μl of a phosphate buffered saline to 90 μl of a cell suspension as a control. Culture solution 1 cultured for 24 hours
Celltiter for 00 μl
96 (manufactured by Promega), and the cell growth inhibitory activity of the decomposed extract on the cell line was examined using the activity of mitochondrial dehydrogenase as an index. At this time, the cell growth inhibitory activity was calculated as cell growth inhibition rate (%) = 100− (absorbance at 590 nm of culture solution cultured for 24 hours after addition of the decomposed extract / absorbance at 590 nm of control) ×
Represented by 100. The results are shown as graphs in FIGS.

【0018】図1はT細胞性白血病細胞RPMI840
2に対して分解抽出物を各種濃度で添加したときの24
時間後における白血病細胞増殖阻害率を表わしたもので
ある。RPMI8402に対する結果では、Bの100
μg/mlの濃度に対してのみ約20%の増殖阻害を示
し、それ以下の濃度では細胞増殖阻害の効果は認められ
なかった。図2はT細胞性白血病細胞MOLT4に対す
る細胞増殖阻害効果を示したものである。この図から、
Bの50μg/mlの濃度に対して10%程度の細胞増
殖阻害効果が示され、100μg/mlの濃度では、A
及びBに対してそれぞれ10%程度、80%程度の細胞
増殖阻害効果が示されていることが分る。図3はT細胞
性白血病細胞Jurkatに対する細胞増殖阻害の結果
を示すグラフである。この結果から、A及びBの50μ
g/mlの濃度に対して約10〜25%の細胞増殖阻害
の効果を示し、100μg/mlの濃度では、A及びB
に対してそれぞれが50%程度、80%程度の細胞増殖
阻害効果を示すことが分る。また、図4はB細胞性白血
病細胞NALM6に対して各種濃度の分解抽出物を添加
したときの24時間後における阻害率を示すグラフであ
る。この図から分るように、A及びBのいずれの分解抽
出物に対しても細胞増殖阻害の効果は認められなかっ
た。
FIG. 1 shows the T cell leukemia cell RPMI840.
24 when various concentrations of the decomposed extract were added to
It shows the leukemia cell growth inhibition rate after time. The results for RPMI8402 show that B
Only at a concentration of μg / ml, about 20% of growth inhibition was observed, and at concentrations lower than that, no effect of cell growth inhibition was observed. FIG. 2 shows the cell growth inhibitory effect on T cell leukemia cells MOLT4. From this figure,
A cell growth inhibitory effect of about 10% was shown with respect to a concentration of 50 μg / ml of B, and at a concentration of 100 μg / ml, A
It can be seen that cell growth inhibitory effects of about 10% and about 80% are shown for B and B, respectively. FIG. 3 is a graph showing the results of cell growth inhibition on T cell leukemia cells Jurkat. From these results, it was found that A and B
at a concentration of 100 μg / ml A and B at a concentration of 100 μg / ml
It can be seen that each of them exhibits a cell growth inhibitory effect of about 50% and about 80%. FIG. 4 is a graph showing the inhibition rate after 24 hours when various concentrations of the decomposed extract were added to B cell leukemia cell NALM6. As can be seen from this figure, no cell growth inhibitory effect was observed on any of the degraded extracts A and B.

【0019】以上の結果から、140〜220℃の加圧
熱水で分解抽出されたグループIIの凍結乾燥物から、
蒸留水で抽出して得られる成分(A)、また凍結乾燥粉
末をエタノールを用いて脂溶性成分を除去したのち、さ
らに蒸留水で抽出した成分(B)について、いずれも白
血病細胞の増殖阻害に効果を示すことが分る。特にT細
胞性白血病細胞への増殖阻害効果が効果的であり、また
抽出成分Bの効果が大きいことが分かった。このことか
ら、加圧熱水によって得られるグループIIの分解抽出
物には白血病細胞の増殖を阻害する効果があることが認
められた。
From the above results, from the lyophilized product of Group II decomposed and extracted with hot pressurized water at 140 to 220 ° C.,
The component (A) obtained by extraction with distilled water, and the lyophilized powder obtained by removing the fat-soluble component using ethanol and then the component (B) extracted with distilled water, both inhibit the growth of leukemia cells. You can see the effect. In particular, it was found that the growth inhibitory effect on T-cell leukemia cells was effective, and that the effect of the extracted component B was large. From this, it was confirmed that the decomposition extract of Group II obtained by pressurized hot water had an effect of inhibiting the growth of leukemia cells.

【0020】[0020]

【発明の効果】本発明によれば、植物木質組織粉末に1
40℃以下に加熱した加圧熱水を接触させ、細胞内含有
成分などの可溶成分を除去したのち、さらに140〜2
20℃の加圧熱水を接触させて得られる分解抽出物は白
血病細胞の増殖を阻害する効果を示す。この分解抽出物
は、少量において白血病細胞増殖阻害剤として用いられ
るが、食物繊維を多く含有しているため一般食品への添
加により機能性食品としての素材としても有用である。
また、製造方法としても、酸やアルカリなどの触媒を用
いない水のみにより容易に得られるため、安全でかつ簡
便な方法である。
According to the present invention, the plant wood tissue powder is
After contacting pressurized hot water heated to 40 ° C. or lower to remove soluble components such as components contained in cells, 140 to 2
The decomposed extract obtained by contacting hot pressurized water at 20 ° C. has an effect of inhibiting the growth of leukemia cells. The decomposed extract is used as a leukemia cell growth inhibitor in a small amount, but contains a large amount of dietary fiber, and thus is useful as a material as a functional food when added to general foods.
Also, the production method is a safe and simple method because it can be easily obtained only with water without using a catalyst such as an acid or an alkali.

【図面の簡単な説明】[Brief description of the drawings]

【図1】 T細胞性白血病細胞RPMI8402に対し
て各種濃度の分解抽出物を添加したときの24時間後に
おける細胞増殖阻害率を示すグラフ。
FIG. 1 is a graph showing the cell growth inhibition rate after 24 hours when various concentrations of a decomposed extract were added to T cell leukemia cells RPMI8402.

【図2】 T細胞性白血病細胞MOLT4に対して各種
濃度の分解抽出物を添加したときの24時間後における
細胞増殖阻害率を示すグラフ。
FIG. 2 is a graph showing the cell growth inhibition rate after 24 hours when various concentrations of a decomposed extract were added to T cell leukemia cells MOLT4.

【図3】 T細胞性白血病細胞Jurkatに対して各
種濃度の分解抽出物を添加したときの24時間後におけ
る細胞増殖阻害率を示すグラフ。
FIG. 3 is a graph showing the cell growth inhibition rate after 24 hours when various concentrations of a decomposed extract were added to T cell leukemia cells Jurkat.

【図4】 B細胞性白血病細胞NALM6に対して各種
濃度の分解抽出物を添加したときの24時間後における
細胞増殖阻害率を示すグラフ。
FIG. 4 is a graph showing the cell growth inhibition rate after 24 hours when various concentrations of a decomposed extract were added to B cell leukemia cells NALM6.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 安藤 浩毅 鹿児島県姶良郡隼人町小田1445番地1 鹿児島県工業技術センター内 (72)発明者 古川 郁子 鹿児島県姶良郡隼人町小田1445番地1 鹿児島県工業技術センター内 (72)発明者 國生 徹郎 鹿児島県姶良郡隼人町小田1445番地1 鹿児島県工業技術センター内 (56)参考文献 特開 平3−49662(JP,A) 特開 平3−205402(JP,A) 特開 平4−71466(JP,A) 特開 平4−218501(JP,A) 米国特許4997817(US,A) (58)調査した分野(Int.Cl.7,DB名) A61K 35/78 A61K 31/715 BIOSIS(DIALOG) CA(STN) MEDLINE(STN)──────────────────────────────────────────────────の Continuing on the front page (72) Inventor Hiroki Ando 1445-1 Oda, Hayato-cho, Aira-gun, Kagoshima Prefecture Inside the Kagoshima Industrial Technology Center (72) Ikuko Furukawa 1-445-1, Oda, Hayato-cho, Aira-gun, Kagoshima Kagoshima Kogyo Inside the Technology Center (72) Inventor Tetsuro Kunio 1445-1 Oda, Hayato-cho, Aira-gun, Kagoshima Prefecture Inside the Kagoshima Prefectural Industrial Technology Center (56) References JP-A-3-49662 (JP, A) JP-A-3-205402 , A) JP-A-4-71466 (JP, A) JP-A-4-218501 (JP, A) US Patent 4,978,817 (US, A) (58) Fields investigated (Int. Cl. 7 , DB name) 35/78 A61K 31/715 BIOSIS (DIALOG) CA (STN) MEDLINE (STN)

Claims (2)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 植物木質組織由来の非セルロース性食物
繊維を主成分としてなる白血病細胞増殖阻害剤。
1. A leukemia cell proliferation inhibitor comprising a non-cellulosic dietary fiber derived from a woody tissue of a plant as a main component.
【請求項2】 植物木質組織粉末に、100〜140℃
の加圧熱水を接触させて可溶成分を抽出除去したのち、
その残留分に140〜220℃の加圧熱水を接触させて
分解及び抽出を行わせ、非セルロース性食物繊維を分離
することを特徴とする白血病細胞増殖阻害剤の製造方
法。
2. A method for preparing a plant wood tissue powder at 100 to 140 ° C.
After extracting and removing soluble components by contacting hot pressurized water of
A method for producing a leukemia cell growth inhibitor, comprising separating non-cellulosic dietary fiber by contacting the residue with hot pressurized water at 140 to 220 ° C. to cause decomposition and extraction.
JP11148440A 1999-05-27 1999-05-27 Leukemia cell growth inhibitor and method for producing the same Expired - Lifetime JP3026435B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11148440A JP3026435B1 (en) 1999-05-27 1999-05-27 Leukemia cell growth inhibitor and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11148440A JP3026435B1 (en) 1999-05-27 1999-05-27 Leukemia cell growth inhibitor and method for producing the same

Publications (2)

Publication Number Publication Date
JP3026435B1 true JP3026435B1 (en) 2000-03-27
JP2000336036A JP2000336036A (en) 2000-12-05

Family

ID=15452853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11148440A Expired - Lifetime JP3026435B1 (en) 1999-05-27 1999-05-27 Leukemia cell growth inhibitor and method for producing the same

Country Status (1)

Country Link
JP (1) JP3026435B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6017896B2 (en) * 2012-09-06 2016-11-02 日本製紙株式会社 Method for producing arabinose
JP2015071544A (en) * 2013-10-01 2015-04-16 王子ホールディングス株式会社 Method of producing furfural from biomass

Also Published As

Publication number Publication date
JP2000336036A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
Parul et al. In vitro nitric oxide scavenging activity of methanol extracts of three Bangladeshi medicinal plants
KR100361187B1 (en) The hematopoietic, myeloid protecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng
Moharram et al. Polyphenols of Melaleuca quinquenervia leaves–pharmacological studies of grandinin
PL126984B1 (en) Method of obtaining cyclodextrin-matricaria inclusion complex compounds
RU2088255C1 (en) Method of preparing the plant dry extract
KR20140138882A (en) A method for isolating dietary fiber arabinogalactan and arabinogalactan in combination with flavonoid dihydroquercetin (taxifolin) from conifer wood species or hardwood including butt logs and bark
JP3026435B1 (en) Leukemia cell growth inhibitor and method for producing the same
CN109536283B (en) Preparation method and application of storax oil for improving quality
CN108464986B (en) Application of geniposide in relieving skeletal muscle fibrosis
Liao et al. The potential, challenges, and prospects of the genus Spirulina polysaccharides as future multipurpose biomacromolecules
KR102264494B1 (en) Composition for preventing, improving or treating osteoarthritis using mixture of natural ingredients
KR101320149B1 (en) Urushiol reduction disposed lacquer, lacquer extract by using the same and Method of manufacturing the same
Yang et al. Optimization of Supercritical Fluid Extraction of Phenolic Compounds from Peach Blossom (Amygdalus Persica) by Response Surface Methodology.
KR20190101063A (en) Composition containing natural material extract for preventing and improving respiratory organ disease
JPH11323326A (en) Active oxygen eliminating agent, skin protecting agent and discoloration inhibitor
KR102092872B1 (en) Composition for anti-inflammation comprising Geumgangsong subcritical water extract as effective component
Mannani et al. In vitro antifungal activity of Iranian propolis against Microsporum canis, M. gypseum and M. nanum
KR20100074849A (en) Composition for suppressing production of biogenic amines
CN114366752B (en) Therapeutic effect of morinda-oligosaccharide 5-glycan monomer Hex5 on osteosarcoma
CN113576963B (en) Extraction method for Butyrospermum parkii extract and extract obtained by extraction method
JP3150835B2 (en) Process for producing lignan glycosides and lignans
EP1975171A1 (en) Anti-tumor agent and immunostimulating agent
Lavitschka et al. In vitro cytotoxicity and antioxidant activity of Agaricus subrufescens extracts
Hur et al. Changes in aurantio-obtusin and glucoaurantio-obtusin content in Cassiae Semen via treatment with a crude enzyme extract from Aspergillus usamii
Aljazy et al. Antioxidant Activity and the Laxative Agent of Red Hawthorn (Crataegus Sumbollis) in Jam Industry

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080128

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090128

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090128

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100128

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100128

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110128

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120128

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130128

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 14

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term